

AnnaBidiol Corp.
A Delaware Corporation
(617) 517-6310

Annual Report

For the Years Ended December 31, 2025, and 2024

Prepared in accordance with
OTC Pink Basic Disclosure Guidelines

TABLE OF CONTENTS

	Page
Forward Looking Statements	3
Organizational Structure	3
Management	3
Balance Sheets as of December 31, 2025, and 2024	4
Statements of Operations for the Years Ended December 31, 2025, and 2024	5
Statement of Stockholders' Equity for the Years Ended December 31, 2025, and 2024	6
Statements of Cash Flows for the Years Ended December 31, 2025, and 2024	7
Notes to the Financial Statements	8
OTC Pink Basic Disclosures	11
Signatures	16

Forward-Looking Statements

This Company Profile contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made herein that may be considered forward-looking include statements incorporating terms such as "expects," "believes," "intends," "anticipates," and similar terms that relate to future events, performance, or results of the Company, including without limitation, statements made regarding expected future results. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from management's present expectations or projections. These risks and uncertainties include but are not limited to, customer and supplier relationships; prices; competition; ability to realize anticipated benefits from initiatives taken; market demand; litigation and other liabilities; and economic, political, governmental, and technological factors affecting the Company's operations, tax rate, markets, products, services, and prices, among others.

Organizational Structure

AnnaBidiol Corp. (the "Company" or "Asiana") was incorporated in the State of Delaware on Sept. 22, 2009, as DragonTel Holding, Inc., which thereafter changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp., effective upon FINRA approval on January 8, 2018.

Management

David D Peralta - Mr. Peralta currently serves as President, sole Director, and interim Chief Executive Officer of the Company. He served as the President and sole Director of the Company from December 9, 2019, through October 4, 2024, and served as interim Chief Executive Officer, effective October 30, 2023, through October 4, 2024.

On October 4, 2024, The Board of Directors held a Special Meeting in which it appointed Daniel M Taylor and Karen Guerra as directors and Dan Taylor as interim CEO in conjunction with a proposed merger agreement. Concurrent with these appointments, Mr. Peralta resigned as an officer and director of the Company.

On November 8, 2024, Mr. Taylor and Ms. Guerra appointed Mr. Peralta to again serve as the sole Director and interim Chief Executive Officer of the Company. Following this appointment, both Mr. Taylor and Ms. Guerra resigned their positions.

**ANNABIDIOL CORP.
UNAUDITED BALANCE SHEETS**

	December 31, 2025	December 31, 2024
ASSETS		
Current Assets		
Cash	294	15,064
Accounts receivable	-	35,150
Total Current Assets	294	50,214
Total Assets	\$ 294	\$ 50,214
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities		
Accounts payable and accrued expenses	\$ 129,991	\$ 161,872
Total Liabilities	129,991	161,872
Commitments and Contingencies	-	-
Stockholders' Deficit		
Preferred Series A, \$0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding	-	-
Common Stock, \$0.0001 par value; 495,000,000 shares authorized, 40,190,306 and 39,990,306 shares issued and outstanding as of December 31, 2025, and 2024, respectively	4,019	3,999
Subscriptions payable	-	200,000
Additional paid-in capital	5,561,151	5,361,171
Accumulated deficit	(5,561,151)	(5,676,828)
Total Stockholders' Deficit	(129,697)	(111,658)
Total Liabilities and Stockholders' Deficit	\$ 294	\$ 50,214

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF OPERATIONS

	For the Years Ended	
	December 31, 2025	December 31, 2024
Revenue	\$ -	\$ -
Cost of Goods Sold	-	-
Gross Profit	-	-
Operating Expenses:		
General administrative	8,039	17,516
Professional and consulting fees	10,000	112,952
Total operating expenses	18,039	130,468
Loss from operations	(18,039)	(130,468)
Other Income (Expense)	-	-
Net Loss Before Income Taxes	(18,039)	(130,468)
Income tax	-	-
Net Loss After Income Taxes	\$ (18,039)	\$ (130,468)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	40,174,964	39,990,306
Loss per Common Share - Basic and Diluted	\$ (0.00)	\$ (0.00)

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF STOCKHOLDERS' DEFICIT

	Shares Outstanding Preferred A	Preferred A	Shares Outstanding Common	Common Stock	Subscription Payable	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit
Balance as of December 31, 2024	-	\$ -	39,990,306	\$ 3,999	\$ 200,000	\$ 5,361,171	\$ (5,676,828)	\$ (111,658)
Issuance of common stock for subscriptions payable	-	-	200,000	20	(200,000)	199,980	-	-
Net loss	-	-	-	-	-	-	(18,039)	(18,039)
Balance as of December 31, 2025	<u>-</u>	<u>\$ -</u>	<u>40,190,306</u>	<u>\$ 4,019</u>	<u>\$ -</u>	<u>\$ 5,561,151</u>	<u>\$ (5,694,867)</u>	<u>\$ (129,697)</u>
	Shares Outstanding Preferred A	Preferred A	Shares Outstanding Common	Common Stock	Subscription Payable	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit
Balance as of June 30, 2024	500,000	\$ 50	39,990,306	\$ 3,999	\$ -	\$ 5,361,121	\$ (5,557,701)	\$ (192,531)
Proceeds from subscriptions payable	-	-	-	-	200,000	-	-	200,000
Surrender of Preferred A shares	(500,000)	(50)	-	-	-	50	-	-
Net income	-	-	-	-	-	-	(130,468)	(130,468)
Balance as of December 31, 2024	<u>-</u>	<u>\$ -</u>	<u>39,990,306</u>	<u>\$ 3,999</u>	<u>\$ 200,000</u>	<u>\$ 5,361,171</u>	<u>\$ (5,676,828)</u>	<u>\$ (111,658)</u>

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF CASH FLOWS

	Years Ended December 31,	
	2025	2024
Cash Flows from Operating Activities		
Net income (loss)	\$ (18,039)	\$ (130,468)
Changes in operating assets and liabilities:		
Accounts receivable	35,150	(20,150)
Accounts payable and accrued expenses	(31,881)	(41,999)
Net Cash Used in Operating Activities	(192,617)	(192,617)
Cash Flows from Investing Activities	-	-
Cash Flows from Financing Activities		
Advances by majority shareholder	-	7,750
Advances by potential acquisition company	-	5,000
Proceeds from subscriptions payable	-	185,000
Net Cash Provided by Financing Activities	-	197,750
Net Increase (Decrease) in Cash	(14,770)	5,133
Cash, Beginning of Period	15,064	9,931
Cash, End of Period	\$ 294	\$ 15,064
Supplemental Disclosure of Cash Flow Information:		
Cash paid for interest	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -
Non-Cash Activities		
Retirement of Preferred A shares	\$ -	\$ 50

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
December 31, 2025

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

AnnaBidiol Corp. (the “Company” or “Asiana”) was incorporated in the State of Delaware on September 22, 2009, as DragonTel Holding, Inc., which thereafter changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp., effective on FINRA approval on January 8, 2018. The Company is a Delaware Corporation organized for the purpose of engaging in any lawful business.

The Company has had minimal business operations or activity since 2011, when it was associated with GJC Holdings, Inc., a wholly owned subsidiary that was divested. The subsidiary’s activities ceased in June 2011 with the liquidation of all remaining assets and liabilities.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts and valuations of intangible assets, among others. Actual results could differ from those estimates.

Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Concentrations and credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance may, at times, exceed federally insured limits. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

Risk and Uncertainties

The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations are subject to significant risks and uncertainties, including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the date of purchase and money market accounts to be cash equivalents. As of December 31, 2025, and 2024, the Company had \$294 and \$15,064 of cash and no cash equivalents, respectively.

Revenue Recognition

The Company currently has no realized revenue from operations. We account for product revenue in accordance with Accounting Standards Codification 606, Revenue Recognition, and all related interpretations. Revenue is recognized when the following criteria are met:

- Identification of the contract, or contracts, with a customer
- Identification of the performance obligations in the contract
- Determination of the transaction price
- Allocation of the transaction price to the performance obligations in the contract
- Recognition of revenue when, or as, we satisfy the performance obligation.

Any revenue received that does not yet meet the above recognition standards is recorded to unearned revenue and held as a liability until recognition occurs.

Impairment of Long-Lived Assets

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value of assets to be used and fair value less disposal cost for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset's market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued loss associated with assets used to generate revenue.

Income Taxes

Income taxes are provided in accordance with ASC 740 Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Provision for income taxes consists of federal and state income taxes in the United States. Due to the uncertainty as to the realization of benefits from our deferred tax assets, including net operating loss carryforwards and other tax credits, we have a full valuation allowance reserved against such assets. We expect to maintain this full valuation allowance, at least in the near term.

The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the years ended December 31, 2025, and 2024.

Earnings per Share Policy

The basic computation of loss per share is based on the weighted average number of shares outstanding during the period presented in accordance with ASC 260, "Earnings Per Share." The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period, plus the common stock equivalents arising from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the period. Common stock equivalents are not included in the diluted earnings per share calculation when their effect is anti-dilutive.

Share-Based Payments and Stock-Based Compensation

Share-based compensation awards, including stock options and restricted stock awards, are recorded at estimated fair value on the applicable award's grant date, based on the estimated number of awards that are expected to vest. The grant date fair value is amortized on a straight-line basis over the time in which the awards are expected to vest or immediately if no vesting is required. Share-based compensation awards issued to non-employees for services are recorded at either the fair value of the services rendered or the fair value of the share-based payments, whichever is more readily determinable. The fair value of restricted stock awards is based on the fair value of the stock underlying the awards on the grant date, as there is no exercise price.

Recent Accounting Pronouncements

Management believes the impact of recently issued standards and updates, which are not yet effective, will not have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

NOTE 3 – STOCKHOLDERS' EQUITY

The total number of common shares authorized that may be issued by the Company is 495,000,000 shares with a par value of \$0.0001 per share. The Company is authorized to issue 5,000,000 shares of preferred Series A stock with a par value of \$0.0001 per share. The Company is authorized to issue 5,000,000 shares of preferred Series B stock with a par value of \$0.0001 per share. As of December 31, 2025, and 2024, there were 40,190,306 and 39,990,306 shares of Common Stock issued and outstanding, respectively. As of December 31, 2025, and 2024, there were 0 (zero) Preferred Series A shares issued and outstanding. As of December 31, 2025, and 2024, there were 0 (zero) Preferred Series B shares issued and outstanding.

Between October 7, 2024, and October 29, 2024, the Company received aggregate proceeds of \$185,000 out of a total of \$200,000 for the purchase of 200,000 shares of the Company's common stock at \$1.00 per share. These shares were issued on January 28, 2025.

Series A and Series B Preferred Stock

Series A – There are 5,000,000 shares of this Series authorized, with no shares issued and outstanding as of December 31, 2025, and 2024. The Series A shares have a deemed purchase price of \$1.00 per share, for liquidation purposes, and the shares have priority over all other preferred stock in liquidation.

The Series A has Super Majority voting power, voting with the common stock as one class, the equivalent of 60% of the common stock at all times. It cannot have its rights and privileges changed unless 75% of the Series A shares vote to do so. There are no redemption rights, no cumulative dividends, and no conversion rights under the Series A Certificate of Designation.

Series B – There are 5,000,000 shares of this series authorized, and no shares issued and outstanding. The shares are junior to the Series A in liquidation priority but senior to all other shares. They have a deemed purchase price of \$1.00 per share for liquidation and dividend payments. Dividends are payable at 15% per annum, cumulative, in cash or common stock. The shares are convertible to common stock on a one-for-one basis, at the holder's option, or automatically, as forced conversion, if the common shares are traded at a daily closing price of \$1.00 per share or more for 45 consecutive trading days. The shares are redeemable at \$1.00 per share plus accrued and unpaid dividends on notice by the Company. A Pledge secures the shares on the assets of the Company for liquidation and merger purposes.

NOTE 4 – MERGER AGREEMENT WITH TARGATEK, INC.

On October 4, 2024, the Company entered into an agreement to acquire Targatek, Inc. and authorized the completion of the merger into a wholly owned subsidiary. However, at and immediately after such date, Targatek provided inaccurate information, failed to fulfill key obligations required for issuing the correct shares in the merger, and failed to deliver accurate financial statements prepared in accordance with Generally Accepted Accounting Principles (GAAP).

Termination of Merger Agreement

On or about October 7, 2025, Targatek Inc. held a board meeting and, at the sole election of Targatek Inc. and its board of directors, elected not to comply with the Agreement and Plan of Merger dated October 4, 2024, and terminated any further discussions or attempts to close under its terms. The decision not to comply with the merger agreement was made unilaterally by Targatek Inc.

NOTE 4 – SUBSEQUENT EVENTS

We have evaluated all events that occurred after the balance sheet date through the date when our financial statements were issued to determine if they must be reported. Management has determined that, other than those disclosed, there were no additional reportable subsequent events to be disclosed.

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

AnnaBidiol Corp.

PO Box 7
Marblehead, MA 01945
(617) 517-6310
info.DRSI@yahoo.com

SIC Code: 8748 - Business Consulting Services, Not Elsewhere Classified

Annual Report

For the Period Ending: December 31, 2025
(the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

As of December 31, 2025, the number of shares outstanding of our Common Stock was 40,190,306.

As of December 31, 2024, the number of shares outstanding of our Common Stock was 39,990,306.

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934, and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities.

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

ITEM 1: Name of the issuer and its predecessors (if any)

AnnaBidiol Corp. (the “Company”) was incorporated in the State of Delaware on Sept. 22, 2009, and is currently active and in good standing in all states in which it operates. A listing of all previous names used by the Company is as follows:

AnnaBidiol Corp.	January 8, 2018 – Present
Strategic Pharma Information Sciences Inc.	July 25, 2016 – January 8, 2018
Asiana Dragons, Inc.	April 26, 2011 – July 25, 2016
DragonTel Holding, Inc.	September 22, 2009 – April 26, 2011

There have not been any trading suspension orders issued by the SEC since its inception.

There have been no stock splits, stock dividends, recapitalizations, mergers, acquisitions, spin-offs, or reorganizations in the past 12 months, and none are currently anticipated.

The Company’s principal executive office is:
PO Box 7
Marblehead, MA 01945

Check box if the principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

ITEM 2: Security Information

Transfer Agent

Mountain Share Transfer, Inc.
service@mountainsharetransfer.com
2030 Powers Ferry Rd. SE., Suite #212
Atlanta, GA 30339
Phone: (404) 474-3110

Trading symbol: ACBD

Exact title and class of securities outstanding: Common equity
CUSIP: 03571L106
Par or Stated Value: \$0.0001
Total common shares authorized: 495,000,000 as of March 30, 2026
Total common shares outstanding: 40,190,306 as of March 30, 2026
Total number of shareholders of record: 495* as of March 30, 2026

*Shareholder of record may not include all shares held in “street name.”

Preferred Stock Series A

Par or Stated Value: \$0.0001
Total shares authorized: 5,000,000 as of March 30, 2026
Total shares outstanding: none as of March 30, 2026

Preferred Stock Series B

Par or Stated Value: \$0.0001
Total shares authorized: 5,000,000 as of March 30, 2026
Total shares outstanding: none as of March 30, 2026

Security Description:

Each of the Company's common shares has the right to one vote per share. There are currently no preemption or dividend rights attributable to the Company's common shares.

The Series A Preferred shares have Super Majority voting power, voting with the common stock as one class, the equivalent of 60% of the common stock at all times. It cannot have the rights and privileges changed unless 75% of the shares of Series A vote to do so. There are no redemption rights, no cumulative dividends, and no conversion rights under the Series A Certificate of Designation.

The Series B Preferred shares are junior to the Series A in liquidation priority but senior to all other shares. They have a deemed purchase price of \$1.00 per share for liquidation and dividend payments. Dividends are payable at 15% per annum, cumulative, in cash or common stock. The shares are convertible to common stock on a one-for-one basis, at the holder's option, or automatically, as forced conversion, if the common shares are traded at a daily closing price of \$1.00 per share or more for 45 consecutive trading days. The shares are redeemable at \$1.00 per share plus accrued and unpaid dividends on notice by the Company. A Pledge secures the shares on the assets of the Company for liquidation and merger purposes.

There have not been any material modifications to the rights of the holders of the Company's securities that have occurred over the reporting period covered by this report.

ITEM 3: Issuance History

On January 28, 2025, the Company issued an aggregate of 200,000 shares of the Company's common stock for previously received proceeds of \$200,000.

ITEM 3A: Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years: No: Yes: (If yes, you must complete the table below)

Shares Outstanding Opening Balance:									
Date: December 31, 2023									
Common: 39,990,306									
Preferred: 500,000									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR - Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
10/4/2024	Returned	500,000	Preferred	-	No	PRLTA LLC (1)	N/A	N/A	N/A
1/28/2025	New	100,000	Common	\$1.00	No	Thomas W Regan Jr.	Cash	Restricted	4(a)(2)
1/28/2025	New	50,000	Common	\$1.00	No	Robert Crivelli	Cash	Restricted	4(a)(2)
1/28/2025	New	50,000	Common	\$1.00	No	Biren Zaverchand	Cash	Restricted	4(a)(2)
Shares									
Shares Outstanding on Date of This Report:									
Date December 31, 2025									
Ending Balance Common: 40,190,306									
Preferred: 0									

(1) David D Peralta is the Managing Member of PRLTA, LLC

ITEM 3B: Convertible Debt

The following is a complete list of the Company's Convertible Debt, which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

ITEM 4: Issuer's Business, Products, and Services

The Company has been focused, through an intensive campaign, on searching for asset acquisitions, strategic partnerships, joint ventures, and other objectives, among those objectives and our primary focus to invest or partner with companies that we believe are undervalued, underdeveloped, or whose growth potential is significant and potentially underappreciated and undervalued. Under these or similar circumstances, the possibility of delivering sustainable value for our shareholders could be achievable but remains a work in progress.

Additionally, the Company provides consulting services to customers looking for potential business acquisitions.

The Company does not have any subsidiaries, parents, or affiliated companies.

ITEM 5: Facilities

The Company does not currently lease any facilities. Unless it acquires partners, forms a JV, or converts to a business that requires a physical location, the Company will continue to operate virtual offices. We believe that a virtual presence provides substantial savings and the ability to pivot our business strategy as opportunities arise.

ITEM 6: Officers, Directors, and Control Persons

Name of: Officer, Director, or Control Person	Affiliation with Company (e.g., Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding ⁽¹⁾
David D Peralta, PRLTA LLC ⁽²⁾	Interim CEO, Director, and significant shareholder	PO Box 7 Marblehead, MA 01945	36,820,000	Common	91.61%

(2) Based on 40,190,306 shares of common stock outstanding as of March 30, 2026

(3) David D Peralta is the Managing Member of PRLTA, LLC

ITEM 7: Legal/Disciplinary History

None of the persons listed above in Item 6 has, in the last 10 years, been the subject of:

- 1) an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
- 2) the entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended, or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance, or banking activities.
- 3) a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated.
- 4) Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or
- 5) an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
- 6) a U.S Postal Service false representation order, or a temporary restraining order, or a preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

There are no material pending legal proceedings, to which the issuer is a party or of which any of its property is the subject.

ITEM 8: Third-Party Providers

Legal Counsel

Michael A. Littman, Attorney at Law
P.O. Box 1839
Arvada, CO 80001

Accountant

Chris Kohler
Chris Kohler Consulting Inc.
10252 Springstone Rd
Fishers, IN 46055

ITEM 9: Financial Statements

A. This Disclosure Statement was prepared by:

Name: Chris Kohler Consulting, Inc.

Title: Accountant

Relationship to Issuer: Contract Accountant and Corporate Secretary

B. The following financial statements were prepared in accordance with:

IFRS

U.S. GAAP

C. These financial statements for this reporting period were prepared by:

Name: Chris Kohler Consulting, Inc.

Title: Accountant

Relationship to Issuer: Contract Accountant and Corporate Secretary

Describe the qualifications of the person or persons who prepared the financial statements: Financial and Accounting Expert with a Masters Degree in Accountancy

The issuer is providing the following financial statements:

- a) Balance Sheets as of December 31, 2025, and 2024.
- b) Statements of Operations for the Years Ended December 31, 2025, and 2024.
- c) Statement of Stockholders' Equity (Deficit) for the Years Ended December 31, 2025, and 2024.
- d) Statements of Cash Flows for Years Ended December 31, 2025, and 2024.
- e) Notes to the financial statements.

ITEM 10: Certification

Principal Executive Officer:

I, David D Peralta, Interim Chief Executive Officer and Director, certify that:

1. I have reviewed the Disclosure Statements for December 31, 2025, and 2024 of AnnaBidiol Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements and other financial information included or incorporated by reference in this disclosure statement fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 31, 2026

/s/ David D Peralta

David D Peralta

Interim Chief Executive Officer